255 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28421763	5	Synthetic Approaches to the New Drugs Approved During 2015.	Pfizer
27560285	28	Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.	Institute of Materia Medica
27396490	41	Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes.	East China University of Science and Technology
27190600	48	Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.	Merck Research Laboratories
27106708	130	The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.	Merck Research Laboratories
26546218	13	Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.	Merck Research Laboratories
26200936	39	Applications of Fluorine in Medicinal Chemistry.	Bristol-Myers Squibb Research and Development
26372650	9	Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes.	National Institute of Pharmaceutical Education and Research-Ahmedabad
26222445	5	Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.	Glaxosmithkline
25147615	108	Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes.	Xuanzhu Pharma
25164763	95	Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.	Shanghai Institute of Materia Medica
26005541	33	Design, Synthesis, and Pharmacological Evaluation of Fusedß-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.	Chinese Academy of Sciences
25815154	13	Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold.	University Park Nottingham
25838146	5	Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors.	Southern Medical University
25596166	4	Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.	Sumitomo Dainippon Pharma
24948564	5	Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.	Jamia Hamdard
25457126	55	(R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling.	Chinese Academy of Sciences
25443644	10	Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate.	TBA
24617858	239	Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).	University of Antwerp
24099035	5	Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?	Chuv-Unil
24675378	33	Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors.	M.S. University of Baroda
24660890	12	Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.	Merck
24044354	11	A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.	Tufts University
24900744	39	Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery.	Sanofi-Aventis
23434133	18	Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.	Chinese Academy of Science
23594271	68	Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.	Tufts University Sackler School of Biomedical Sciences
23416006	28	Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors.	Bristol-Myers Squibb Research and Development
22503246	32	Long-acting peptidomimetics based DPP-IV inhibitors.	Zydus Research Centre
23072865	59	Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.	Toray Industries
23121075	119	P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.	University of Antwerp
23025999	33	Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.	Takeda California
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
22959556	57	Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.	Mitsubishi Tanabe Pharma
22938786	86	Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.	Dainippon Sumitomo Pharma
22850208	60	Dipeptidyl peptidase-4 inhibitor withß-amino amide scaffold: synthesis, SAR and biological evaluation.	Dong-A Pharm.
22853995	57	4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.	Tufts University School of Medicine
22824762	39	Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group.	Mitsubishi Tanabe Pharma
22525314	159	Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.	University of Antwerp (Ua)
22475866	19	Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.	Chinese Academy of Sciences
22377519	23	An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors.	Prosidion
21764322	33	Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.	Takeda Pharmaceutical
21218817	52	Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.	Takeda Pharmaceutical
21106276	18	The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.	Chinese Academy of Sciences
20718420	167	Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.	National Health Research Institutes
20058865	59	Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.	Mcgill University
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
19375196	22	Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.	Sichuan University
19217790	68	Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.	Matrix Laboratories
18243000	43	Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.	Taisho Pharmaceutical
18485703	37	3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.	Boehringer Ingelheim Pharma
18346892	42	Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.	Takeda California
17962025	24	Discovery of long-acting N-(cyanomethyl)-N-alkyl-L-prolinamide inhibitors of dipeptidyl peptidase IV.	Minase Research Institute
18331795	44	Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors.	Merck
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18039579	59	Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.	Ono Pharmaceutical
18201067	276	Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.	Merck Research Laboratories
17869513	112	Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.	Merck Research Laboratories
17331715	19	Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.	Korea Research Institute of Chemical Technology
17822893	61	(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.	Pfizer
17113301	83	Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors.	Mitsubishi Pharma
15357972	30	Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents.	Korea Research Institute of Chemical Technology
14584950	132	Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases.	University of Antwerp (Uia)
9622551	14	Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26.	Universit£
8642568	28	Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.	Boehringer Ingelheim Pharmaceuticals
12270155	56	Development of potent and selective dipeptidyl peptidase II inhibitors.	University of Antwerp (Uia)
10915049	22	1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors.	Novartis Institute For Biomedical Research
10098663	81	Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.	University of Tokyo
	27	2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV	TBA
22177783	122	Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.	Argenta Discovery
22019046	35	Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.	Sanwa Kagaku Kenkyusho
21996520	149	7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.	Bristol-Myers Squibb Research and Development
21996517	5	Molecular dynamics simulations and MM/GBSA methods to investigate binding mechanisms of aminomethylpyrimidine inhibitors with DPP-IV.	Graduate University of The Chinese Academy of Sciences
21865048	29	2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.	Dainippon Sumitomo Pharma
21711053	106	Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?	University of Antwerp (Ua)
21741847	20	Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.	Takeda Pharmaceutical
21570283	29	Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.	Dong-A Pharm.
21478015	6	Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-relateda-glucosidase inhibitors and liver X receptor antagonists.	The University of Tokyo
21388136	9	Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.	Tufts University Sackler School of Graduate Biomedical Sciences
21435872	5	Aza-annulation on the 16-dehydropregnenolone, via tandem intermolecular aldol process and intramolecular Michael addition.	Central Drug Research Institute
24900243	44	Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors.	TBA
21334204	26	Discovery of potent dipeptidyl peptidase IV inhibitors derived fromß-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.	Shandong University of Traditional Chinese Medicine
21324688	36	1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.	Pfizer
21320777	375	Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors.	Merck Research Laboratories
21306895	46	Discovery ofß-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.	Korea Research Institute of Chemical Technology
21186796	83	Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.	Takeda California
21163664	24	Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.	Takeda Pharmaceutical
21074430	53	Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.	Dainippon Sumitomo Pharma
20800322	10	Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors.	East China University of Science and Technology
20833042	51	Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors.	Bristol-Myers Squibb Research and Development
20684603	101	Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.	Bristol-Myers Squibb
20598534	105	Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.	Bristol-Myers Squibb
20488704	28	Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.	Shanghai Hengrui Pharmaceuticals
20488702	21	Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.	Shanghai Hengrui Pharmaceuticals
20483603	106	(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.	National Health Research Institutes
20031408	9	Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.	F. Hoffmann-La Roche
20031405	19	Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.	F. Hoffmann-La Roche
20000418	1	Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.	Instituto De Qu£Mica M£Dica (Csic)
19833514	104	The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements.	Santhera Pharmaceuticals (Switzerland)
19576767	142	From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.	Santhera Pharmaceuticals (Switzerland)
19539471	130	Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.	Merck
19515557	47	Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.	Santhera Pharmaceuticals (Switzerland)
19482472	30	Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.	Phenomix
	14	4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV	TBA
19285862	30	Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.	Pfizer
19275964	64	(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.	Pfizer
19269819	102	Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.	National Health Research Institutes
19261480	113	Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.	National Health Research Institutes
18996694	30	Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.	Korea Research Institute of Chemical Technology
18819797	24	(3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.	Toray Industries
18783201	27	Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.	Tufts University
18650094	12	Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.	Institut De Recerca BiomèDica De Barcelona
18602260	177	Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors.	Ranbaxy Research Laboratories
18570365	29	The many roles for fluorine in medicinal chemistry.	Merck Research Laboratories
18556199	234	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.	University of Antwerp
18556198	125	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors.	University of Antwerp
18524582	52	Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design.	Merck Research Laboratories
18457385	41	Recent developments in fragment-based drug discovery.	Astex Therapeutics
18243422	35	Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors.	Korea Research Institute of Chemical Technology
18207285	26	A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors.	National Health Research Institutes
18068977	3	Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.	St. John'S University
18052023	30	8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.	Boehringer Ingelheim Pharma
17977724	83	Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.	Pfizer
17958345	75	Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates.	University of Antwerp
17937986	39	Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.	Bristol-Myers Squibb Research and Development
17883259	17	Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.	Chinese Academy of Sciences
17851076	77	4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.	Merck Research Laboratories
17827003	68	Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.	Merck Research Laboratories
17562364	150	Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors.	Merck Research Laboratories
17544668	55	Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: oxadiazolyl ketones.	Lg Life Sciences
17502141	25	Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors.	Merck Research Laboratories
17434732	99	Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).	Merck Research Laboratories
17433672	16	Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.	Merck Research Laboratories
17418568	50	1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.	F. Hoffmann-La Roche
17317162	60	[(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.	Mitsubishi Pharma
17293118	30	Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration.	Minase Research Institute
17292611	21	Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV.	Minase Research Institute
17194587	106	3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.	National Health Research Institutes
17174090	50	Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.	Genentech
17055271	18	Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor.	Tufts University School of Medicine
16844373	25	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines.	Laboratory of Medicinal Chemistry University of Antwerp
16722626	94	cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.	Pfizer
16321524	8	In silico fragment-based discovery of DPP-IV S1 pocket binders.	Santhera Pharmaceuticals
16168640	82	2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV.	Glaxosmithkline
16115768	11	New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.	Pfizer
16085416	45	Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7.	Activx Biosciences
16084722	55	Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors.	Activx Biosciences
15927466	52	Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.	National Health Research Institutes
15863294	36	1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors.	Mitsubishi Pharma
15380217	87	Potent and selective proline derived dipeptidyl peptidase IV inhibitors.	Merck
15324904	52	Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.	Merck
15324903	49	Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors.	Merck
15293982	12	Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.	Merck Research Laboratories
15139769	87	Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors.	University of Antwerp
15012982	129	Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors.	Merck Research Laboratories
14980678	88	Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.	Merck Research Laboratories
14684294	79	4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.	Merck
12801240	105	1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.	Novartis Institute For Biomedical Research
12036346	12	1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.	TBA
32008883	41	Anti-diabetic drugs recent approaches and advancements.	Mizoram University
32452679	53	Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.	Haisco Pharmaceutical Group
30694668	5	Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.	East China University of Science and Technology
27438064	29	Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.	Boehringer Ingelheim Pharma
27670099	43	Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors.	Merck Research Laboratories
30642693	78	Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.	Guangxi Medical University
10090787	25	Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.	University of Antwerp (Uia)
31812034	17	Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 inhibition mechanism and insulinotropic activities.	Government Arts College
31336309	68	Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.	Guangxi Medical University
31301567	3	Discovery, synthesis, and in vitro evaluation of a novel bioactive peptide for ACE and DPP-IV inhibitory activity.	University of Mysore
9873385	3	A potent dipeptide inhibitor of dipeptidyl peptidase IV.	Tanabe Seiyaku
31393718	26	Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein ?.	Mcgill University
30343953	27	Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents.	Xi'An Jiaotong University
31683103	16	Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.	Ural Federal University Named After The First President of Russia B.N. Eltsin
24457090	2	Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.	China Pharmaceutical University
22707871	12	Kinetic studies of novel inhibitors of endomorphin degrading enzymes.	TBA
17458948	16	Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines.	Tufts University School of Medicine
9464355	59	Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.	University of Tokyo
30056037	4	Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.	Siberian Branch of The Russian Academy of Sciences
29609120	44	Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.	Chinese Academy of Sciences
29373269	28	Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.	Shanghai Jiao Tong University
29078995	27	Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation.	The First Affiliated Hospital of Guangzhou Medical University
28826083	108	Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.	University of Warwick
29773502	4	Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.	Chinese Academy of Sciences
28128944	96	Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase? (PI3K?) Inhibitors.	University Park Nottingham
28579121	35	Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.	Takeda Pharmaceutical
28442252	62	Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.	Ranbaxy Laboratories
21406033	4	The evaluation of inhibitive effectiveness of the tumour necrosis factor-a converting enzyme selective inhibitors by HPLC.	Huazhong University of Science and Technology
28135235	71	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.	Novartis Institutes For Biomedical Research
28259376	11	Green synthesis, inhibition studies of yeast a-glucosidase and molecular docking of pyrazolylpyridazine amines.	University of The Punjab
24003220	1	Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches.	Sanofi Oncology
9195869	28	Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.	Laboratorium FÜR Organische Chemie
20017516	11	Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.	Stanford University
19450983	74	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.	Universite Degli Studi Di Firenze
17616632	11	Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.	Nih
15582469	16	Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases.	University of Alabama At Birmingham
18760609	66	Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.	Philipps University Marburg
19630403	19	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia (dagger) dagger Coordinates of the PDE10A crystal structures have been depo	Pfizer
19409795	186	Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores.	Biocryst Pharmaceuticals
19422229	125	Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.	Novartis
19328688	12	Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.	Roche R & D Center(China)
19457666	34	Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.	Vitae Pharmaceuticals
19464884	34	Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood.	Wyeth Research
19406640	58	Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.	Gsk
19348415	52	Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).	Gsk
19143533	44	Discovery and Structure-Activity Relationships of Trisubstituted Pyrimidines/Pyridines as Novel Calcium-Sensing Receptor Antagonists.	Bristol-Myers Squibb
19256504	18	Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.	Astrazeneca
19193011	49	Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors (dagger).	Johnson & Johnson Pharmaceutical
19056263	34	Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.	Gsk
19071018	72	Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.	Gsk
16288880	41	Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.	Fujisawa Pharmaceutical
16844380	76	Synthesis and structure activity relationships of novel non-peptidic metallo-aminopeptidase inhibitors.	Enscmu
9784112	87	Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.	Parke-Davis Pharmaceutical Research